Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
University of California, Davis
National Cancer Institute (NCI)
AbbVie
Wake Forest University Health Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
AbbVie
M.D. Anderson Cancer Center
North Eastern German Society of Gynaecological Oncology
Ohio State University Comprehensive Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
AbbVie
AbbVie
RemeGen Co., Ltd.
TORL Biotherapeutics, LLC
Mayo Clinic
Massachusetts General Hospital
Gradalis, Inc.
AbbVie
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Corcept Therapeutics
Wake Forest University Health Sciences
Brown University
Corcept Therapeutics
M.D. Anderson Cancer Center
University Health Network, Toronto
University of Washington
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
OncoC4, Inc.
The Netherlands Cancer Institute
CanariaBio Inc.
CanariaBio Inc.
The University of Hong Kong
The University of Hong Kong
Beijing Biostar Pharmaceuticals Co., Ltd.
University of Pittsburgh
Universitaire Ziekenhuizen KU Leuven
University of Chicago
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Instituto do Cancer do Estado de São Paulo
Roswell Park Cancer Institute
Thomas Jefferson University